| EN

COSELA:trilaciclib hydrochloride for injection

COSELA:trilaciclib hydrochloride for injection

Indications:

It is suitable for patients with extensive-stage small cell lung cancer, who have not received systemic chemotherapy before. It is administered before receiving platinum-based drugs combined with etoposide regimen to reduce the incidence of myelosuppression caused by chemotherapy. 


Cosela® (trilaciclib hydrochloride for injection) is the world's first innovative drug jointly developed by 澳门PG电子游戏APP官方网站 and G1 Therapeutics, which is administered before chemotherapy for comprehensive myeloprotection against chemotherapy damages and was certified as a "Breakthrough Therapy" by FDA. It was launched in the United States in Feb. 2021. In Aug. 2020, 澳门PG电子游戏APP官方网站 entered into an exclusive license agreement with G1 to obtain rights for the development and commercialization of Cosela® for all indications in Greater China.